Actavis builds brand business, generates generics growth
This article was originally published in Scrip
Executive Summary
Actavis hosted its annual investor day on 31 January to lay the groundwork for 2014 and beyond with a focus on expanding its brand name portfolio while growing the generics business that makes up the largest segment of its revenue, which is expected to total $10bn this year.